Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18499691 | 0.88 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL26230924 | 0.88 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL19915498 | 0.88 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL27104500 | 0.85 | MEN1 (0.42) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL25124522 | 0.85 | SMN1; SMN2 (0.45) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL19372449 | 0.84 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL25603436 | 0.83 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL24833962 | 0.83 | GAA (0.40) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL12245290 | 0.83 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL24220965 | 0.81 | SIRT2 (0.44) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230001006-A1 | AMHRII-BINDING ANTIBODY DRUG CONJUGATES AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS | EXELIXIS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-9931420-B2 | Methods of making DLL3 antibody drug conjugates | ABBVIE STEMCENTRX LLC (US) | 2018-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001006-A1 | AMHRII-BINDING ANTIBODY DRUG CONJUGATES AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS | LHCGR, INHA, GNRHR | RAB9A 4031/4885SMN1; SMN2 2709/4885NPC1 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.